Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Women Often Opt To Surgically Remove Their Breasts, Ovaries To Reduce Cancer Risk
Many women at high risk for breast or ovarian cancer are choosing to undergo surgery as a precautionary measure to decrease their cancer risk, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
generic viagra online
Lantheus Medical Imaging, Inc. Completes Enrollment Of CaRES Registry To Further Evaluate Definity(R) In Patients With Suboptimal Echocardiograms
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, announces that it has completed patient enrollment of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), the first, multicenter Phase IV observational registry that evaluates the use of ultrasound imaging agents in routine clinical practice. The 1,060 patients who were enrolled at 15 sites in the U.S. were 18 years old or older and required DEFINITY® Vial for (Perflutren Lipid Microsphere) injectable suspension-enhanced echocardiography because of a previous suboptimal, unenhanced echocardiogram.
News of the day
St. Jude Medical Completes Implants In U.S. Study Of Deep Brain Stimulation For Parkinson's Disease
St. Jude Medical, Inc. (NYSE:STJ) announced the completion of patient implants in its U.S. pivotal clinical study of deep brain stimulation (DBS) for the symptomatic treatment of Parkinson"s disease, a neurological disorder affecting approximately 6.3 million people worldwide that progressively diminishes a person"s control over his or her movements. The announcement was made at the Movement Disorder Society"s 13th International Congress of Parkinson"s Disease and Movement Disorders in Paris.
Endocrinology

Argenta Discovery Announces Entry Into Phase I For First Candidate From Collaboration With AstraZeneca To Develop Improved Inhaled Bronchodilators

Argenta Discovery Limited, the respiratory drug discovery and development company, announces a major milestone in its joint programme with AstraZeneca aimed at identifying improved inhaled bronchodilators to treat chronic obstructive pulmonary disease (COPD). This important milestone marks the first candidate drug from the collaboration to enter Phase I safety and tolerability studies. This drug candidate is on track to enter Phase II "proof-of-concept" trials later this year. The original agreement between the two companies was announced in January 2007. Scientists from the two companies are collaborating to identify long-acting muscarinic (M3) antagonist (LAMA) and dual-acting muscarinic antagonist-í²2 agonist (MABA) candidate drugs. These compounds will be developed as once-daily, inhaled mono or combination therapies. AstraZeneca will be responsible for the development and worldwide commercialisation of products arising out of the collaboration. Dependent upon success, Argenta is eligible for further development, regulatory and sales milestone payments. Royalties will also be payable to Argenta. Commenting on the progress, Dr. Christopher Ashton, Argenta Discovery"s CEO, said, "The programme continues to deliver beyond the expectations of both parties and we are firmly on track to achieve our joint strategic goals for the programme." Chronic Obstructive Pulmonary Disease Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow obstruction that is progressive and current therapies, including inhaled corticosteroids, fail to treat disease progression. COPD is a leading cause of morbidity and mortality worldwide with an overall prevalence in adults over 40 years currently estimated at between 9 and 10%. Unlike many other major diseases, deaths due to COPD are increasing and the World Health Organisation (WHO) estimates by 2030 that COPD will be the third leading cause of mortality and fifth leading cause of morbidity in the world. Thus there is a high level of unmet medical need for this progressive and debilitating disease. About Argenta Discovery Argenta Discovery was founded in August 2000. Argenta has expertise in chronic respiratory diseases, including Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. The company has generated a portfolio of pre-clinical bronchodilator and anti-inflammatory programmes with the goal of demonstrating clinical proof-of-concept. In 2009, Argenta completed its first Phase II clinical trial with ADC4022, an investigational medicine for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. Argenta also has a contract research division that provides integrated drug discovery services to a range of leading pharmaceutical and biotechnology companies worldwide. Argenta employs approximately 160 people and is based in Harlow, Welwyn Garden City and Slough, UK. For more information about Argenta Discovery, please visit www.argentadiscovery.com AstraZeneca


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009